RxDoctor Payments Data

James Abanishe, MD

Psychiatry · New New, NYNPI 1992053573

Payments from drug & device makers

$12,660in general payments, 2019–2025

Across 63 payments — averaging $200.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$10K
  • Almatica Pharma LLC$2K
  • AbbVie$692
  • Avanir Pharmaceuticals, Inc.$125
  • Otsuka America Pharmaceutical, Inc.$52
  • E.r. Squibb & Sons, L.L.C.$27
  • plus $35 from 2 others

What the payments were for

  • Consulting fees$9,58076%
  • Travel & lodging$1,46012%
  • Food & beverage$1,54812%
  • Education$731%

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,660 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$112,675
Medicare patients
137
Services billed
832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl12$17,249
Desvenlafaxine Succinate ErDesvenlafaxine Succinate157$11,922
TrintellixVortioxetine Hydrobromide12$6,778
VyvanseLisdexamfetamine Dimesylate12$4,272
Bupropion XlBupropion Hcl180$3,797
Doxepin Hcl57$2,846
Eszopiclone57$2,421
Aripiprazole114$2,208
Duloxetine Hcl89$2,098
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine76$1,969
Olanzapine OdtOlanzapine42$1,773
Atomoxetine Hcl17$1,674
Quetiapine Fumarate124$1,666
Olanzapine46$1,570
Fluoxetine Hcl122$1,518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$692$17,24912 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$15$11,05124 claims
Almatica Pharma LLCSertraline Hcl$1,784$46386 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in New New

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →